CENTRAL DISTRICT, Hong Kong
- Nov. 23, 2020
-- 1Globe Biomedical's research analysts have no left no stone unturned in a detailed and comprehensive report on Molecular Colorectal Cancer cells backed by historical analysis and projected challenges.
1Globe Biomedical's research team carried out an in-depth analysis to understand all of the factors shaping its growth trajectory using advanced cell testing and this particular research is likely to play a vital role in the years to come.
1Globe Biomedical's Chief Medical Officer commented on the Molecular Colorectal Cancer saying "The outbreak of the COVID-19 pandemic which has now caused massive problems of unexpected proportions has shifted the global focus towards the healthcare market. The world's governments are closely working with healthcare institutions and pharmaceutical companies to provide effective treatments for the virus."
1Globe Biomedical's Chief Medical Officer also added "As a result of the ongoing COVID-19 pandemic, the focus has been shifted to medical priorities across healthcare institutions with treatment for COVID-19 infected patients being the most urgent to treat, and we think that this is sure to impact the growth of Molecular Colorectal Cancer cells."
About Us - 1Globe Biomedical
1Globe Biomedical is a clinical stage biotechnology company pioneering the development of receptor T (1BioCARs™) therapies for cancer. Led by a world-class management team with significant experience in cell therapy, we are developing a pipeline of "off-the-shelf"
receptor T cell therapy candidates with the goal of delivering readily available cell therapy faster, more reliably and at greater scale to more patients.http://1globe-biomedical.com/about-us/history/index.html